Try a new search

Format these results:

Searched for:



Total Results:


Eyebrow Lifting From High-Intensity, High-Frequency, Parallel Ultrasound Beams

Wang, Jordan V; Bajaj, Shirin; Kauvar, Arielle; Geronemus, Roy G
PMID: 37093677
ISSN: 1524-4725
CID: 5465022

Prospective Evaluation of the Safety and Efficacy of Thermomechanical Fractional Injury for Perioral Rhytides

Wang, Jordan V; Bajaj, Shirin; Steuer, Alexa; Orbuch, David; Geronemus, Roy G
BACKGROUND:Perioral rhytides can be treated with laser and energy-based devices. More recently, a novel fractional thermomechanical skin rejuvenation system was developed to cause controlled thermal injury through direct heat transfer. OBJECTIVE:A prospective clinical trial evaluated the safety and efficacy of a thermomechanical fractional injury device (Tixel 2, Novoxel, Netanya, Israel) for perioral rhytides. MATERIALS AND METHODS:Subjects with moderate-to-severe perioral rhytides were enrolled and underwent 4 monthly treatments. RESULTS:Twenty-three subjects were enrolled and completed all study visits. Mean age was 62.5 years, and 100.0% were women. Fitzpatrick Skin Types I-IV were included. For Fitzpatrick Wrinkle Classification System (FWCS), mean baseline score was 6.9. Per investigator, there was a mean 1.9-grade improvement in FWCS at 3-month follow-up ( p < .0001). At 3-month follow-up, 8.7% (n = 2) of subjects had a 3-grade improvement, 69.6% (n = 16) had a 2-grade improvement, and 21.7% (n = 5) had a 1-grade improvement. For physician Global Aesthetics Improvement Scale at 3-month follow-up, 69.6% (n = 16) had 76% to 100% improvement, 13.0% (n = 3) had 51% to 75% improvement, and 17.4% (n = 4) had 26% to 50% improvement. There were no severe adverse events, and subjects experienced minimal pain. CONCLUSION:A novel device using thermomechanical fractional injury was demonstrated to be safe and effective in the treatment of perioral rhytides.
PMID: 36946689
ISSN: 1524-4725
CID: 5537162

High-Intensity, High-Frequency, Parallel Ultrasound Beams for Submental Lifting

Wang, Jordan V; Bajaj, Shirin; Geronemus, Roy G; Kauvar, Arielle
PMID: 36946702
ISSN: 1524-4725
CID: 5502502

Obtaining Access to Tumors of the Conchal Bowl and External Auditory Canal Via Postauricular Sulcus Incision

Bajaj, Shirin; Rubin, Samuel J; Urken, Mark L; Geronemus, Roy G
PMID: 36857161
ISSN: 1524-4725
CID: 5462302

Melanoma surveillance for high-risk patients via telemedicine: Examination of real-world data from an integrated store-and-forward total body photography and dermoscopy service

Tan, Andrea; Greenwald, Elizabeth; Bajaj, Shirin; Belen, Debbie; Sheridan, Taylor; Stein, Jennifer A; Liebman, Tracey N; Bowling, Adrian; Polsky, David
PMID: 33515626
ISSN: 1097-6787
CID: 4775632

Preventing and Managing Complications in Dermatologic Surgery: Procedural and Post-surgical Concerns

Strickler, Allen G; Shah, Payal; Bajaj, Shirin; Mizuguchi, Richard; Nijhawan, Rajiv I; Odueyungbo, Mercy; Rossi, Anthony; Ratner, Désirée
PMID: 33493570
ISSN: 1097-6787
CID: 4767012

Preventing Complications in Dermatologic Surgery: Pre-surgical Concerns

Strickler, Allen G; Shah, Payal; Bajaj, Shirin; Mizuguchi, Richard; Nijhawan, Rajiv I; Odueyungbo, Mercy; Rossi, Anthony; Ratner, Désirée
Cutaneous surgery has become critical to comprehensive dermatologic care, and dermatologists must therefore be equipped to manage the risks associated with surgical procedures. As complications may occur at any point along the continuum of care, assessing, managing and preventing risk from beginning to end becomes essential. This review focuses on preventing surgical complications pre- and post-operatively as well as during the surgical procedure.
PMID: 33497750
ISSN: 1097-6787
CID: 4767132

Technological advances for the detection of melanoma: Part II. Advances in molecular techniques

Fried, Lauren; Tan, Andrea; Bajaj, Shirin; Liebman, Tracey N; Polsky, David; Stein, Jennifer A
The growth of molecular technologies analyzing skin cells and inherited genetic variations has the potential to address current gaps in both diagnostic accuracy and prognostication in melanoma patients or in individuals at risk for developing melanoma. In part II of this continuing medical education article, novel molecular technologies are reviewed. These have been developed as adjunct tools for melanoma management and include the Pigmented Lesion Assay (PLA), myPath Melanoma, and DecisionDx-Melanoma tests, and genetic testing in patients with a strong familial melanoma history. These tests are commercially available and marketed as ancillary tools for clinical decision-making, diagnosis, and prognosis. Here we review fundamental principles behind each test, discuss peer-reviewed literature assessing their performance, and highlight the utility and limitations of each assay. The goal of this article is to provide a comprehensive, evidence-based foundation for clinicians regarding management of patients with difficult pigmented lesions.
PMID: 32360759
ISSN: 1097-6787
CID: 4439082

Technological advances for the detection of melanoma: Advances in diagnostic techniques

Fried, Lauren; Tan, Andrea; Bajaj, Shirin; Liebman, Tracey N; Polsky, David; Stein, Jennifer A
Managing the balance between accurately identifying early stage melanomas while avoiding obtaining biopsy specimens of benign lesions (ie, overbiopsy) is the major challenge of melanoma detection. Decision making can be especially difficult in patients with extensive atypical nevi. Recognizing that the primary screening modality for melanoma is subjective examination, studies have shown a tendency toward overbiopsy. Even low-risk routine surgical procedures are associated with morbidity, mounting health care costs, and patient anxiety. Recent advancements in noninvasive diagnostic modalities have helped improve diagnostic accuracy, especially when managing melanocytic lesions of uncertain diagnosis. Breakthroughs in artificial intelligence have also shown exciting potential in changing the landscape of melanoma detection. In the first article in this continuing medical education series, we review novel diagnostic technologies, such as automated 2- and 3-dimensional total body imaging with sequential digital dermoscopic imaging, reflectance confocal microscopy, and electrical impedance spectroscopy, and we explore the logistics and implications of potentially integrating artificial intelligence into existing melanoma management paradigms.
PMID: 32348823
ISSN: 1097-6787
CID: 4588132

Melanoma Prognosis - Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition

Bajaj, Shirin; Donnelly, Douglas; Call, Melissa; Johannet, Paul; Moran, Una; Polsky, David; Shapiro, Richard; Berman, Russell; Pavlick, Anna; Weber, Jeffrey; Zhong, Judy; Osman, Iman
BACKGROUND:The American Joint Committee on Cancer (AJCC) maintains that the eighth edition of its Staging Manual (AJCC8) has improved accuracy compared to the seventh (AJCC7). However, there are concerns that implementation may disrupt analysis of active clinical trials for stage III patients. We used an independent cohort of melanoma patients to test the extent to which AJCC8 has improved prognostic accuracy compared to AJCC7. METHODS:We analyzed a cohort of 1,315 prospectively enrolled patients. We assessed primary tumor and nodal classification of stage I-III patients using AJCC7 and AJCC8 to assign disease stages at diagnosis. We compared recurrence-free (RFS) and overall survival (OS) using Kaplan-Meier curves and log-rank tests. We then compared concordance indices of discriminatory prognostic ability and area under the curve (AUC) of 5-year survival to predict RFS/OS. All statistical tests were two-sided. RESULTS:Stage IIC continued to have worse outcomes than those for stage IIIA patients, with 5-year RFS of 26.5% (95%CI=12.8-55.1%) vs. 56.0% (95%CI=37.0-84.7%) by AJCC8 (P = 0.002). For stage I, removing mitotic index as T classification factor decreased its prognostic value, although not statistically significantly (RFS C-index=0.63 [95%CI=0.56-0.69] to 0.56 [95%CI=0.49-0.63], P = 0.07; OS C-index=0.48 [95%CI=0.38-0.58] to 0.48 [95%CI=0.41-0.56], P = 0.90). For stage II, prognostication remained constant (RFS C-index=0.65 [95%CI=0.57-0.72]; OS C-index=0.61 [95%CI=0.50-0.72]), and. For stage III, AJCC8 yielded statistically significantly enhanced prognostication for RFS (C-index=0.65 [95%CI=0.60-0.70] to 0.70 [95%CI=0.66-0.75], P = 0.01). CONCLUSIONS:Compared with AJCC7, we demonstrate that AJCC8 enables more accurate prognosis for patients with stage III melanoma. Restaging a large cohort of patients can enhance the analysis of active clinical trials.
PMID: 31977051
ISSN: 1460-2105
CID: 4274042